A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (≥6 To <18 Years of Age)

Trial Profile

A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (≥6 To <18 Years of Age)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2018

At a glance

  • Drugs Guselkumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms PROTOSTAR
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 19 Jun 2018 Planned initiation date changed from 6 Jun 2018 to 6 Jul 2018.
    • 18 Apr 2018 Planned End Date changed from 23 Apr 2025 to 2 Jun 2025.
    • 18 Apr 2018 Planned initiation date changed from 25 May 2018 to 6 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top